CommercialPrior AuthHigh impact
Reminder: GLP-1 Utilization Management
BlueCross BlueShield of South Carolina·SC · Endocrinology, Cardiology, Bariatric Surgery +4 more·Prior Authorization
Effective date
Sep 1, 2025
We identified it
Aug 11, 2026
Summary
Effective September 1, 2025, all GLP-1 medications require prior authorization and must be prescribed only for FDA-approved indications by authorized providers with diabetes management expertise. GLP-1 agents prescribed for non-FDA-approved uses or by unauthorized providers will be denied. Additionally, Zepbound and Wegovy will not be covered under plans that exclude weight loss medications, regardless of the specific diagnosis (sleep apnea or cardiovascular disease), due to drug classification-based coverage determinations.
Action Required
By September 1, 2025: (1) Billing team must update billing software to require prior authorization for ALL GLP-1 medications across all FDA-approved indications (Type 2 diabetes, chronic weight management, cardiovascular risk reduction, obstructive sleep apnea). (2) Create pre-claim verification process to confirm prescribing provider is authorized with documented diabetes/obesity management credentials. (3) Implement claim denial protocols for GLP-1 prescriptions from unauthorized providers or for off-label uses. (4) Update claim edits to deny Zepbound and Wegovy claims under plans with weight loss medication exclusions, regardless of diagnosis code (ICD-10 codes for sleep apnea, cardiovascular disease, obesity, or diabetes). (5) Front desk and clinical staff must verify provider authorization status before scheduling/processing appointments. (6) Communicate to all providers that GLP-1 prescriptions require prior auth effective this date. Failure to obtain prior authorization will result in automatic claim denials and member liability.